AbbVie (ABBV) Stock Forecast, Price Target & Predictions
ABBV Stock Forecast
AbbVie stock forecast is as follows: an average price target of $174.04 (represents a -13.18% downside from ABBV’s last price of $200.47) and a rating consensus of 'Buy', based on 31 wall street analysts offering a 1-year stock forecast.
ABBV Price Target
The average price target for AbbVie (ABBV) is $174.04 based on 1-year price targets from 31 Wall Street analysts in the past 3 months, with a price target range of $228.00 to $127.00. This represents a potential -13.18% downside from ABBV's last price of $200.47.
ABBV Analyst Ratings
According to 31 Wall Street analysts, AbbVie's rating consensus is 'Buy'. The analyst rating breakdown for ABBV stock is 0 'Strong Buy' (0.00%), 21 'Buy' (67.74%), 10 'Hold' (32.26%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
AbbVie Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 31, 2024 | Evan David Seigerman | BMO Capital | $228.00 | $201.50 | 13.15% | 13.73% |
| Oct 31, 2024 | Charlie Yang | Bank of America Securities | $210.00 | $201.50 | 4.22% | 4.75% |
| Oct 31, 2024 | Geoff Meacham | Citigroup | $226.00 | $201.50 | 12.16% | 12.74% |
| Oct 18, 2024 | Geoff Meacham | Bank of America Securities | $195.00 | $188.57 | 3.41% | -2.73% |
| Oct 17, 2024 | Courtney Breen | Bernstein | $203.00 | $190.46 | 6.58% | 1.26% |
| Aug 23, 2024 | Christopher Raymond | Raymond James | $209.00 | $197.35 | 5.90% | 4.26% |
| Jul 19, 2024 | Evan Seigerman | BMO Capital | $214.00 | $172.01 | 24.41% | 6.75% |
| Jun 18, 2024 | Christopher Raymond | Raymond James | $190.00 | $171.36 | 10.88% | -5.22% |
| Jun 05, 2024 | Rajesh Kumar | HSBC | $185.00 | $162.14 | 14.10% | -7.72% |
| May 24, 2024 | James Shin | Deutsche Bank | $175.00 | $156.96 | 11.49% | -12.71% |
The latest AbbVie stock forecast, released on Oct 31, 2024 by Evan David Seigerman from BMO Capital, set a price target of $228.00, which represents a 13.15% increase from the stock price at the time of the forecast ($201.50), and a 13.73% increase from ABBV last price ($200.47).
AbbVie Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 5 | 6 | 15 |
| Avg Price Target | $212.40 | $211.83 | $198.00 |
| Last Closing Price | $200.47 | $200.47 | $200.47 |
| Upside/Downside | 5.95% | 5.67% | -1.23% |
In the current month, the average price target of AbbVie stock is $212.40, according to 5 Wall Street analysts offering twelve months forecast. The average price target represents a 5.95% increase as opposed to AbbVie's last price of $200.47. This month's average price target is up 0.27% compared to last quarter, and up 7.27% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 31, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Oct 31, 2024 | Citigroup | Buy | Buy | Hold |
| Oct 18, 2024 | Bank of America Securities | Neutral | Neutral | Hold |
| Oct 17, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Oct 17, 2024 | Bernstein | Outperform | Market Perform | Initialise |
| Oct 09, 2024 | UBS | Neutral | Neutral | Hold |
| Oct 07, 2024 | Wells Fargo | Buy | Buy | Hold |
| Oct 07, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| Oct 07, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Oct 07, 2024 | Barclays | Overweight | Overweight | Hold |
AbbVie's last stock rating was published by Morgan Stanley on Oct 31, 2024. The company gave ABBV a "Overweight" rating, the same as its previous rate.
AbbVie Financial Forecast
AbbVie Revenue Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $13.93B | $13.87B | $12.22B | $15.12B | $14.81B | $14.58B | $13.54B | $14.89B | $14.34B | $13.96B | $13.01B | $13.86B | $12.90B |
| Avg Forecast | $18.20B | $18.27B | $17.67B | $14.44B | $16.93B | $16.97B | $16.47B | $13.58B | $15.70B | $15.30B | $14.90B | $13.19B | $14.77B | $14.28B | $14.02B | $11.93B | $14.03B | $13.72B | $13.54B | $12.17B | $15.33B | $14.96B | $14.66B | $13.61B | $14.95B | $14.30B | $13.63B | $12.77B | $13.70B | $12.72B |
| High Forecast | $18.76B | $18.83B | $18.21B | $14.88B | $17.45B | $17.49B | $16.97B | $13.99B | $16.18B | $15.77B | $15.36B | $13.71B | $15.18B | $14.29B | $14.02B | $11.93B | $14.34B | $13.83B | $13.95B | $12.54B | $15.80B | $14.96B | $14.66B | $13.61B | $14.95B | $14.30B | $13.63B | $12.77B | $13.70B | $12.72B |
| Low Forecast | $17.76B | $17.83B | $17.25B | $14.09B | $16.53B | $16.57B | $16.07B | $13.25B | $15.33B | $14.93B | $14.55B | $12.77B | $14.54B | $14.28B | $14.02B | $11.93B | $13.94B | $13.65B | $13.22B | $11.88B | $14.97B | $14.96B | $14.66B | $13.61B | $14.95B | $14.30B | $13.63B | $12.77B | $13.70B | $12.72B |
| # Analysts | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 12 | 6 | 7 | 4 | 9 | 15 | 9 | 9 | 13 | 13 | 13 | 13 | 7 | 7 | 7 | 7 | 9 | 15 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.02% | 1.02% | 1.00% | 0.99% | 0.99% | 0.99% | 0.99% | 1.00% | 1.00% | 1.02% | 1.02% | 1.01% | 1.01% |
AbbVie's average Quarter revenue forecast for Dec 23 based on 9 analysts is $14.03B, with a low forecast of $13.94B, and a high forecast of $14.34B. ABBV's average Quarter revenue forecast represents a 0.70% increase compared to the company's last Quarter revenue of $13.93B (Sep 23).
AbbVie EBITDA Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 12 | 6 | 7 | 4 | 9 | 15 | 9 | 9 | 13 | 13 | 13 | 13 | 7 | 7 | 7 | 7 | 9 | 15 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $2.44B | $5.11B | $3.10B | $6.03B | $4.97B | $2.03B | $5.03B | $6.83B | $6.41B | $3.98B | $6.71B | $1.19B | $5.42B |
| Avg Forecast | $6.65B | $6.68B | $6.46B | $5.28B | $6.19B | $6.20B | $6.02B | $4.96B | $5.74B | $5.59B | $5.45B | $4.82B | $5.40B | $5.22B | $5.13B | $9.05B | $5.13B | $5.02B | $4.95B | $8.23B | $7.47B | $5.47B | $5.36B | $7.48B | $5.47B | $5.23B | $4.98B | $6.43B | $5.01B | $4.65B |
| High Forecast | $6.86B | $6.88B | $6.66B | $5.44B | $6.38B | $6.39B | $6.21B | $5.12B | $5.92B | $5.77B | $5.62B | $5.01B | $5.55B | $5.22B | $5.13B | $10.86B | $5.24B | $5.06B | $5.10B | $9.87B | $8.96B | $5.47B | $5.36B | $8.97B | $5.47B | $5.23B | $4.98B | $7.71B | $5.01B | $4.65B |
| Low Forecast | $6.49B | $6.52B | $6.31B | $5.15B | $6.04B | $6.06B | $5.88B | $4.85B | $5.60B | $5.46B | $5.32B | $4.67B | $5.32B | $5.22B | $5.13B | $7.24B | $5.09B | $4.99B | $4.83B | $6.58B | $5.97B | $5.47B | $5.36B | $5.98B | $5.47B | $5.23B | $4.98B | $5.14B | $5.01B | $4.65B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.49% | 1.03% | 0.38% | 0.81% | 0.91% | 0.38% | 0.67% | 1.25% | 1.23% | 0.80% | 1.04% | 0.24% | 1.17% |
9 analysts predict ABBV's average Quarter EBITDA for Dec 23 to be $5.13B, with a high of $5.24B and a low of $5.09B. This is 109.97% upper than AbbVie's previous annual EBITDA (Sep 23) of $2.44B.
AbbVie Net Income Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 12 | 6 | 7 | 4 | 9 | 15 | 9 | 9 | 13 | 13 | 13 | 13 | 7 | 7 | 7 | 7 | 9 | 15 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.78B | $2.02B | $239.00M | $2.47B | $3.95B | $924.00M | $4.49B | $4.04B | $3.18B | $766.00M | $3.55B | $36.00M | $2.31B |
| Avg Forecast | $6.87B | $6.38B | $6.99B | $5.02B | $6.32B | $5.84B | $6.44B | $4.64B | $5.77B | $5.66B | $5.66B | $4.61B | $5.25B | $5.17B | $4.55B | $5.40B | $4.95B | $5.08B | $5.02B | $4.91B | $4.42B | $6.33B | $5.88B | $4.46B | $5.81B | $5.69B | $5.46B | $3.40B | $5.05B | $4.89B |
| High Forecast | $7.15B | $6.63B | $7.27B | $5.22B | $6.57B | $6.07B | $6.69B | $4.83B | $6.00B | $5.89B | $5.88B | $5.12B | $5.44B | $5.20B | $4.55B | $6.48B | $4.99B | $5.19B | $5.22B | $5.89B | $5.31B | $6.33B | $5.88B | $5.35B | $5.81B | $5.69B | $5.46B | $4.08B | $5.05B | $4.89B |
| Low Forecast | $6.66B | $6.18B | $6.77B | $4.87B | $6.12B | $5.66B | $6.24B | $4.50B | $5.59B | $5.49B | $5.48B | $4.24B | $5.16B | $5.15B | $4.55B | $4.32B | $4.90B | $4.97B | $4.86B | $3.93B | $3.54B | $6.33B | $5.88B | $3.57B | $5.81B | $5.69B | $5.46B | $2.72B | $5.05B | $4.89B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.35% | 0.40% | 0.05% | 0.56% | 0.62% | 0.16% | 1.01% | 0.70% | 0.56% | 0.14% | 1.04% | 0.01% | 0.47% |
AbbVie's average Quarter net income forecast for Dec 23 is $4.95B, with a range of $4.90B to $4.99B. ABBV's average Quarter net income forecast represents a 178.35% increase compared to the company's last Quarter net income of $1.78B (Sep 23).
AbbVie SG&A Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 12 | 6 | 7 | 4 | 9 | 15 | 9 | 9 | 13 | 13 | 13 | 13 | 7 | 7 | 7 | 7 | 9 | 15 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $3.37B | $3.27B | $3.04B | $3.42B | $3.30B | $5.41B | $3.13B | $3.26B | $3.08B | $3.16B | $2.84B | $3.23B | $2.85B |
| Avg Forecast | $4.29B | $4.31B | $4.17B | $3.41B | $4.00B | $4.00B | $3.89B | $3.20B | $3.71B | $3.61B | $3.52B | $3.11B | $3.49B | $3.37B | $3.31B | $3.76B | $3.31B | $3.24B | $3.20B | $3.42B | $3.56B | $3.53B | $3.46B | $3.11B | $3.53B | $3.37B | $3.22B | $2.72B | $3.23B | $3.00B |
| High Forecast | $4.43B | $4.44B | $4.30B | $3.51B | $4.12B | $4.13B | $4.01B | $3.30B | $3.82B | $3.72B | $3.62B | $3.24B | $3.58B | $3.37B | $3.31B | $4.51B | $3.39B | $3.26B | $3.29B | $4.10B | $4.28B | $3.53B | $3.46B | $3.73B | $3.53B | $3.37B | $3.22B | $3.27B | $3.23B | $3.00B |
| Low Forecast | $4.19B | $4.21B | $4.07B | $3.33B | $3.90B | $3.91B | $3.79B | $3.13B | $3.62B | $3.52B | $3.43B | $3.01B | $3.43B | $3.37B | $3.31B | $3.01B | $3.29B | $3.22B | $3.12B | $2.73B | $2.85B | $3.53B | $3.46B | $2.49B | $3.53B | $3.37B | $3.22B | $2.18B | $3.23B | $3.00B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.04% | 1.02% | 0.89% | 0.96% | 0.94% | 1.56% | 1.01% | 0.92% | 0.91% | 0.98% | 1.04% | 1.00% | 0.95% |
AbbVie's average Quarter SG&A projection for Dec 23 is $3.31B, based on 9 Wall Street analysts, with a range of $3.29B to $3.39B. The forecast indicates a -1.84% fall compared to ABBV last annual SG&A of $3.37B (Sep 23).
AbbVie EPS Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 12 | 6 | 7 | 4 | 9 | 15 | 9 | 9 | 13 | 13 | 13 | 13 | 7 | 7 | 7 | 7 | 9 | 15 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.01 | $1.14 | $0.14 | $1.40 | $2.22 | $0.52 | $2.52 | $2.29 | $1.80 | $0.43 | $2.01 | $0.02 | $1.31 |
| Avg Forecast | $3.88 | $3.60 | $3.94 | $2.84 | $3.57 | $3.29 | $3.63 | $2.62 | $3.26 | $3.20 | $3.19 | $2.60 | $2.96 | $2.92 | $2.57 | $2.25 | $2.79 | $2.87 | $2.83 | $2.51 | $3.56 | $3.57 | $3.32 | $3.14 | $3.28 | $3.21 | $3.08 | $2.81 | $2.85 | $2.76 |
| High Forecast | $4.03 | $3.74 | $4.10 | $2.95 | $3.71 | $3.43 | $3.78 | $2.73 | $3.39 | $3.32 | $3.32 | $2.89 | $3.07 | $2.93 | $2.57 | $2.26 | $2.81 | $2.93 | $2.95 | $2.61 | $3.70 | $3.57 | $3.32 | $3.14 | $3.28 | $3.21 | $3.08 | $2.81 | $2.85 | $2.76 |
| Low Forecast | $3.76 | $3.49 | $3.82 | $2.75 | $3.46 | $3.19 | $3.52 | $2.54 | $3.16 | $3.10 | $3.09 | $2.40 | $2.91 | $2.91 | $2.57 | $2.25 | $2.76 | $2.80 | $2.74 | $2.43 | $3.45 | $3.57 | $3.32 | $3.14 | $3.28 | $3.21 | $3.08 | $2.81 | $2.85 | $2.76 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.35% | 0.40% | 0.06% | 0.39% | 0.62% | 0.16% | 0.80% | 0.70% | 0.56% | 0.14% | 0.72% | 0.01% | 0.47% |
According to 9 Wall Street analysts, AbbVie's projected average Quarter EPS for Dec 23 is $2.79, with a low estimate of $2.76 and a high estimate of $2.81. This represents a 176.53% increase compared to ABBV previous annual EPS of $1.01 (Sep 23).
AbbVie Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PFE | Pfizer | $27.76 | $44.76 | 61.24% | Hold |
| MRK | Merck | $101.87 | $129.47 | 27.09% | Buy |
| BMY | Bristol-Myers Squibb Company | $55.45 | $64.57 | 16.45% | Hold |
| JNJ | Johnson & Johnson | $158.24 | $179.13 | 13.20% | Buy |
| LLY | Eli Lilly and Company | $806.14 | $782.65 | -2.91% | Buy |
| AMGN | Amgen | $316.91 | $293.15 | -7.50% | Buy |
| GILD | Gilead Sciences | $89.84 | $81.32 | -9.48% | Buy |
| ABBV | AbbVie | $200.47 | $174.04 | -13.18% | Buy |
ABBV Forecast FAQ
Is AbbVie a good buy?
Yes, according to 31 Wall Street analysts, AbbVie (ABBV) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 21 'Buy' recommendations, accounting for 67.74% of ABBV's total ratings.
What is ABBV's price target?
AbbVie (ABBV) average price target is $174.04 with a range of $127 to $228, implying a -13.18% from its last price of $200.47. The data is based on 31 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will AbbVie stock go up soon?
According to Wall Street analysts' prediction for ABBV stock, the company can go down by -13.18% (from the last price of $200.47 to the average price target of $174.04), up by 13.73% based on the highest stock price target, and down by -36.65% based on the lowest stock price target.
Can AbbVie stock reach $300?
ABBV's average twelve months analyst stock price target of $174.04 does not support the claim that AbbVie can reach $300 in the near future.
What is AbbVie's current price target trend?
5 Wall Street analysts forecast a $212.4 price target for AbbVie (ABBV) this month, up 5.95% from its last price of $200.47. Compared to the last 3 and 12 months, the average price target increased by 5.67% and decreased by -1.23%, respectively.
What are AbbVie's analysts' financial forecasts?
AbbVie's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $63.95B (high $65.91B, low $62.42B), average EBITDA is $23.38B (high $24.1B, low $22.82B), average net income is $23.24B (high $24.17B, low $22.52B), average SG&A $15.09B (high $15.55B, low $14.73B), and average EPS is $13.11 (high $13.64, low $12.71). ABBV's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $68.57B (high $70.68B, low $66.94B), average EBITDA is $25.07B (high $25.84B, low $24.47B), average net income is $25.27B (high $26.28B, low $24.48B), average SG&A $16.18B (high $16.68B, low $15.8B), and average EPS is $14.26 (high $14.83, low $13.82).
Did the ABBV's actual financial results beat the analysts' financial forecasts?
Based on AbbVie's last annual report (Dec 2022), the company's revenue was $58.05B, which missed the average analysts forecast of $58.57B by -0.88%. Apple's EBITDA was $19.66B, missing the average prediction of $25.78B by -23.73%. The company's net income was $11.84B, missing the average estimation of $21.09B by -43.88%. Apple's SG&A was $15.26B, beating the average forecast of $13.66B by 11.69%. Lastly, the company's EPS was $6.65, missing the average prediction of $13.6 by -51.09%. In terms of the last quarterly report (Sep 2023), AbbVie's revenue was $13.93B, beating the average analysts' forecast of $13.72B by 1.52%. The company's EBITDA was $2.44B, missing the average prediction of $5.02B by -51.31%. AbbVie's net income was $1.78B, missing the average estimation of $5.08B by -65.01%. The company's SG&A was $3.37B, beating the average forecast of $3.24B by 4.16%. Lastly, the company's EPS was $1.01, missing the average prediction of $2.87 by -64.78%